CECorrine F. Elliott

Corrine F. Elliott

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Corrine F. Elliott has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A pooled analysis of phase 2 clinical trials in advanced chordoma

    by Gregory M. Cote, Corrine F. Elliott, Astrid Lipplaa, Hans Gelderblom, Jean-Yves Blay, Axel Le Cesne, Florence Duffaud, Santosh Kesari, Suzanne George, Neeta Somaiah, et al.


  • Open Access

    Designing a Data Science Simulation with ℳℰℛℐ𝒯𝒮: A Primer

    by Corrine F. Elliott, James P. C. Duncan, Tiffany M. Tang, Merle Behr, Karl Kumbier, Bin Yu


  • Open Access

    simChef: High-quality data science simulations in R

    by James Duncan, Tiffany Tang, Corrine F. Elliott, Philippe Boileau, Bin Yu

    SimChef is an R package that empowers data science practitioners to rapidly plan, carry out, and summarize statistical simulation studies in a flexible, efficient, and low-code manner. Drawing substantially from the Predictability, Computability, and Stability (PCS) framework (Yu & Kumbier, 2020), simChef emphasizes the scientific best practices encompassed by PCS by removing many of the administrative burdens of simulation design through: (1) an intuitive tidy grammar of data science simulations; (2) powerful abstractions for distributed simulation processing backed by future (Bengtsson, 2021); and (3) automated generation of interactive R Markdown simulation documentation, situating results next to the workflows needed to reproduce them. Taken together, simChef's capabilities overcome many of the design, computational, and reproducibility hurdles inherent in nearly every data science simulation study.


  • PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design

    by Kristine Broglio, Lale Kostakoglu, Carol Ward, Federico Mattiello, Denis Sahin, Tina Nielsen, Anna McGlothlin, Corrine F. Elliott, Thomas Witzig, Laurie H. Sehn, et al.

    This study’s focus is the association of end-of-therapy (EOT) PET results with progression-free (PFS) and overall survival (OS) in patients with diffuse large B-cell lymphoma receiving first-line chemoimmunotherapy. We develop a Bayesian hierarchical model for predicting PFS and OS from EOT PET-complete response (PET-CR) using a literature-based meta-analysis of 20 treatment arms and a substudy of 4 treatment arms in 3 clinical trials for which we have patient-level data. The PET-CR rate in our substudy was 72%. The modeled estimates for hazard ratio (PET-CR/non-PET-CR) were 0.13 for PFS (95% CI 0.10, 0.16) and 0.10 for OS (CI 0.07, 0.12). Hazard ratios varied little by patient subtype and were confirmed by the overall meta-analysis. We link these findings to designing future clinical trials and show how our model can be used in adapting the sample size of a trial to accumulating results regarding treatment benefits on PET-CR and a survival endpoint.


  • ARTISTRY-3: Effect of nemvaleukin alfa with a less frequent IV dosing schedule as monotherapy and in combination with pembrolizumab and impact on the tumor microenvironment (TME) in patients (pts) with advanced solid tumors.

    by Sarina Anne Piha-Paul, Corrine F. Elliott, Yangchun Du, Julie R. Graham, Monali Desai, Yan Wang, Rita P. Dalal, Nehal J. Lakhani

    TPS2684 Background: Nemvaleukin alfa (nemvaleukin, ALKS 4230) is a novel engineered cytokine that selectively binds the intermediate-affinity interleukin-2 (IL-2) receptor, preferentially activating and expanding antitumor CD8+ T cells and NK effector cells, with minimal effect on regulatory T cells. Nemvaleukin was designed to leverage antitumor effects of the IL-2 pathway while limiting typical IL-2‒associated toxicity. In ARTISTRY-1, the recommended phase 2 dose (RP2D) for nemvaleukin monotherapy of 6 µg/kg IV on days 1 to 5 of a 21-day cycle elicited durable and deep responses in pts with advanced melanoma and renal cell carcinoma (Boni et al. ASCO 2021:abstr 2513). Responses with nemvaleukin plus pembrolizumab were also observed in platinum-resistant ovarian, breast, cervical, gastrointestinal, and genitourinary cancers. ARTISTRY-3 will investigate the effects of nemvaleukin as monotherapy and in combination with pembrolizumab on the TME in pts with advanced solid tumors, and in an additional cohort (Cohort 2), to further assess a less frequent IV dosing schedule for nemvaleukin. Methods: The phase 1/2, open-label ARTISTRY-3 (NCT04592653) study will enroll adults (≥18 years) with select advanced solid tumors, ≥1 accessible lesion for biopsy, ≥1 target lesion (per RECIST v1.1), ECOG PS of 0 or 1, estimated life expectancy of ≥3 months, adequate hematologic reserve, and adequate hepatic and renal function. Primary objectives: to evaluate effects of nemvaleukin monotherapy on the TME (Cohort 1) and to determine RP2D for less frequent dosing schedule (Cohort 2). Additional objectives are to evaluate: efficacy, safety, immunogenicity, and pharmacokinetics of nemvaleukin monotherapy; effects of nemvaleukin plus pembrolizumab on the TME; and correlative biomarkers of nemvaleukin as monotherapy and combination. Following the protocol amendment, additional pts enrolled in Cohort 1 will receive lead-in monotherapy at a dose selected based on results from Cohort 2, and pre- and on-treatment biopsies will be collected for TME assessments. Subsequent cycles will be administered in combination with pembrolizumab, and a biopsy may be collected at cycle 4 or 5. Tumor types eligible for Cohort 2 are selected based on activity observed in the ARTISTRY-1 study. A quantitative system pharmacology model was applied to identify a less frequent schedule for nemvaleukin monotherapy and combination. Cohort 2 will initially assess safety and tolerability of nemvaleukin at 1 dose per 21-day cycle. Two doses per 21-day cycle may be implemented to achieve optimal PK/PD parameters. Bayesian optimal interval design methodology with open enrollment will be applied to facilitate dose escalation decisions. Clinical trial information: NCT04592653.

  • Steric Manipulation as a Mechanism for Tuning the Reduction and Oxidation Potentials of Phenothiazines

    by Corrine F. Elliott, Kate E. Fraser, Susan A. Odom, Chad Risko

    Synthetic chemists customarily tune the redox characteristics of π-conjugated molecules by introducing electron-donating or electron-withdrawing substituents onto the molecular core, or by modifying the length of the π-conjugated pathway. Any steric effects of such efforts on molecular geometry typically affect both the neutral and charged (oxidized or reduced) states indiscriminately. However, in electroactive systems that undergo significant conformational changes upon oxidation or reduction, we can leverage the steric and inductive effects of substitution to attain considerable control over individual redox potentials. Here, we make use of density functional theory to elucidate the interplay between electronic and geometric effects of peripheral substitution on the model system of phenothiazine. For instance, we introduce substituents at positions ortho to the nitrogen atom (positions 1 and 9) to induce steric strain in the radical-cation state without significant effect on the neutral molecule, thereby augmenting the overall ionization potential. Notably, this steric effect persists for electron-donating substituents; the resulting ionization potentials therefore deviate from outcomes foretold by Hammett constants. Moreover, the same procedure has limited effect on electron affinities because of differences in phenothiazines’ relaxation process upon reduction compared to oxidation. Our results promote molecular design guidelines for manipulating redox potentials in classes of electroactive compounds that experience dramatic changes in geometry upon ionization.


  • A stable, highly oxidizing radical cation

    by N. Harsha Attanayake, Aman Preet Kaur, T. Malsha Suduwella, Corrine F. Elliott, Sean R. Parkin, Susan A. Odom

    Highly oxidizing radical cation salts can be used as chemical oxidants in a wide variety of applications. While some are commercial and others can be made, stability has been a problem with many of these organic-based reagents. We sought a method to increase redox potentials of organic compounds, to yield radical cation salts that do not suffer the same instability as their triarylamine counterparts. Using phenothiazines, we (i) blocked the positions para to nitrogen with a substituent containing strong covalent bonds, using an electron-withdrawing group to increase oxidation potential, while at the same time (ii) introduced strain at the positions ortho to nitrogen to further raise the oxidation potential by preventing geometric relaxation of the oxidized state. Here we synthesized the phenothiazine derivative, N-ethyl-1,9-dimethyl-3,7-bis(trifluoromethyl)phenothiazine to test this hypothesis. Indeed, oxidation potentials reflect additive substituent effects, yielding a high-potential redox couple with a stable radical cation. Stability tests in solution and the solid state show that the radical cation form of this phenothiazinium is stable and can be used to oxidize other organic compounds in solution.


  • Feasibility as a mechanism for model identification and validation

    by Corrine F. Elliott, Joshua W. Lambert, Arnold J. Stromberg, Pei Wang, Ting Zeng, Katherine L. Thompson

    As new technologies permit the generation of hitherto unprecedented volumes of data (e.g. genome-wide association study data), researchers struggle to keep up with the added complexity and time commitment required for its analysis. For this reason, model selection commonly relies on machine learning and data-reduction techniques, which tend to afford models with obscure interpretations. Even in cases with straightforward explanatory variables, the so-called ‘best’ model produced by a given model-selection technique may fail to capture information of vital importance to the domain-specific questions at hand. Herein we propose a new concept for model selection, feasibility, for use in identifying multiple models that are in some sense optimal and may unite to provide a wider range of information relevant to the topic of interest, including (but not limited to) interaction terms. We further provide an R package and associated Shiny Applications for use in identifying or validating feasible models, the performance of which we demonstrate on both simulated and real-life data.


  • Top Cited Papers
    Open Access

    Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis

    by Christopher W. Seymour, Jason N. Kennedy, Shu Wang, Chung-Chou H. Chang, Corrine F. Elliott, Zhongying Xu, Scott Berry, Gilles Clermont, Gregory Cooper, Hernando Gomez, et al.

    Quiz Ref ID Sepsis, defined as a dysregulated immune response to infection that leads to acute organ dysfunction, affects millions of individuals per year, and carries a high risk of death even when care is provided promptly.1,2 Although the understanding of the host immune response has advanced considerably, it has not translated into new therapies. A major barrier to progress is the overly broad definition of the syndrome, which encompasses a vast, multidimensional array of clinical and biological features. Different combinations of these features may naturally cluster into previously undescribed subsets or phenotypes that may have different risks for a poor outcome and may respond differently to treatments. However, efforts to determine such phenotypes have remained limited and have focused primarily on patients in the intensive care unit.3-5 In addition, these phenotypes must be identifiable at or soon after hospital presentation to guide treatment.


  • Open Access

    rFSA: An R Package for Finding Best Subsets and Interactions

    by Joshua Lambert, Liyu Gong, F. Elliott Corrine, Katherine Thompson, Arnold Stromberg

    Herein we present the R package rFSA, which implements an algorithm for improved variable selection. The algorithm searches a data space for models of a user-specified form that are statistically optimal under a measure of model quality. Many iterations afford a set of feasible solutions (or candidate models) that the researcher can evaluate for relevance to his or her questions of interest. The algorithm can be used to formulate new or to improve upon existing models in bioinformatics, health care, and myriad other fields in which the volume of available data has outstripped researchers’ practical and computational ability to explore larger subsets or higher-order interaction terms. The package accommodates linear and generalized linear models, as well as a variety of criterion functions such as Allen’s PRESS and AIC. New modeling strategies and criterion functions can be adapted easily to work with rFSA.